
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 27 years ago
Participating Facultyover 27 years ago
Benefits Foregone: Too Much of the Wrong and Too Little of the Rightover 27 years ago
Breast Cancer Epidemiology: An Overviewover 27 years ago
Breast Cancer Stage Cost Analysis in a Managed Care Populationover 27 years ago
Question-and-Answer Sessionover 27 years ago
Selected Abstracts





